Global Ulcerative Colitis Market Size, Share & Industry Trends Analysis Report By Molecule Type (Small Molecules and Biologics), By Disease Type, By Route of Administration, By Regional Outlook and Forecast, 2022 - 2028
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Ulcerative Colitis Market
Market Report Description
The Global Ulcerative Colitis Market size is expected to reach $9 billion by 2028, rising at a market growth of 5.7% CAGR during the forecast period.
The global ulcerative colitis market is primarily driven by an increase in the incidence of inflammatory gastrointestinal illnesses, an increase in ulcerative colitis cases, and the development of ulcerative colitis-specific medications by a large number of important companies. As per the survey conducted by Marc D Basson on Ulcerative Colitis in 2019, ulcerative colitis affects one million persons in the United States. The high prevalence of ulcerative colitis is the driving force behind the development of ulcerative colitis medications. As the prevalence of inflammatory bowel illness rises, demand for ulcerative colitis rises, which is expected to fuel the growth of the ulcerative colitis market.
The most common kind of inflammatory bowel illness, ulcerative colitis (UC), affects a large number of people. It is widespread in most of Europe and North America, but rare in most developing Asian countries. Males are more likely to develop UC, which has a north-to-south variance. One possible cause is disparities in ultraviolet light exposure, which results in relative vitamin D insufficiency in countries near the Arctic. People who reside in lower latitudes are more prone than those who live in higher latitudes to develop UC. According to a study published in the National Center for Biotechnology Information (NCBI) in June 2020, the global incidence of ulcerative colitis is 9 to 20 cases per 100,000 people per year. The annual prevalence ranges from 156 to 291 cases per 100,000 people. Adults are more likely to develop ulcerative colitis. Nonsmokers and individuals who have just quit smoking are more likely to develop ulcerative colitis.
If ulcerative colitis is left untreated for more than 8 years, it can progress to colon cancer. Over-the-counter medications like Imodium treatment can help those with moderate symptoms of this condition. Transcription drugs such as steroid pharmaceuticals and aminosalicylates, on the other hand, are commonly used to treat the illness. In extreme situations, surgery to remove the colon may be required, which also helps to prevent colon cancer. Ulcerative colitis is also treated with several genetically modified medicines. These medications are composed of living organisms that assist to reduce inflammation by targeting inflammatory proteins like cytokines. Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade), and Vedolizumab are among the genetically modified medications authorized by the US FDA for treating the illness (Entyvio).
COVID-19 Impact Analysis
COVID-19 has acted as a threat multiplier in all areas of life. The medical and psychosocial effects of the COVID-19 pandemic and pre-existing medical conditions like acute severe ulcerative colitis are multidirectional and include the effects of COVID-19 and acute severe ulcerative colitis on each other, as well as their effects on patients, their families, the healthcare system, and health-care providers. According to a study published in the Gastroenterology and Hepatology Journal in February 2021, the risk of COVID-19-related side events is greater in patients with ulcerative colitis. It remains a hazard to people with acute severe ulcerative colitis, posing an ever-increasing threat to the worldwide healthcare system. According to a paper published in June 2020 in the Inflammatory Intestinal Diseases Journal, managing inflammatory bowel disease (IBD) patients (Ulcerative Colitis and Crohn's disease) during the COVID-19 pandemic has been difficult.
Market Growth Factors:
Rising incidences of Ulcerative proctitis
Ulcerative proctitis is one of the kinds of ulcerative colitis that is becoming more common. Fine ulcerations in the inner linings of the large intestine mucosa are visible, and it is thought to be the first sign of ulcerative colitis. According to a study published in the United European Gastroenterology Journal in March 2021, the COVID-19 incidence rate per 1,000 patients with inflammatory bowel disease (ulcerative colitis) and the general population was 4.02 and 6.59, respectively. Hospitalization and intensive care unit care were required by 27.29 percent and 5.33 percent of COVID-19-positive inflammatory bowel disease patients, respectively.
The rise in ulcerative colitis patients and commercialization and an infusion of healthcare capital
The availability of sophisticated ulcerative colitis medications as a result of technological breakthroughs, as well as the growing patient pool in need of treatment, are two main catalytic drivers for the market. In addition, increased demand for symptomatic treatments, the influx of enhancing medications into the market, and increased acceptance of steroids and biologics to treat ulcerative colitis are the major trends in the Ulcerative Colitis Market. Due to increased demand for ulcerative colitis, a shortage of medication, tailored therapy, and curative therapy for ulcerative colitis, the ulcerative colitis industry is likely to offer attractive market prospects.
Marketing Restraining Factor:
Concerns about patent expiry and concerns about negative side effects
The expiration of drug patents is posing a constant threat to the industry players and their revenue. There are few trustworthy medications on the market for ulcerative colitis. Failures, on the other hand, occur when patents are not renewed. The pharmaceutical industry generates the most income of any industry. UC medicines have a high level of investment and production. Patent expiration, on the other hand, can have an impact on all of these processes; capital waste is a big factor that can affect revenue rates. The ulcerative colitis market has had a lot of patent failures in recent years. It is resulting in catastrophic losses.
Based on Molecule Type, the market is segmented into Small Molecules and Biologics. In 2021, the Small Molecules segment obtained the maximum revenue share of the Ulcerative Colitis Market. This is due to the large number of important players offering medications for ulcerative colitis treatment and advancement in R&D operations. Moreover, many players are putting heavy investments in creating effective medications, thereby boosting the growth of the segment.
Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. The Moderate UC segment held a significant revenue share of the Ulcerative Colitis Market in 2021. Urgent bowel motions, frequent bowel movements, abdominal pain, and cramps are just a few of the painful and sometimes debilitating symptoms of moderate ulcerative colitis. Managing the symptoms with medication and effective home remedies can enhance the quality of life and help a person avoid flare-ups in the future.
Route of Administration
Based on Route of Administration, the market is segmented into Oral and Injectables. In 2021, the Oral segment garnered the biggest revenue share of the Ulcerative Colitis Market. This is due to increased R&D activities in the pharmaceutical & medical device industry, growing demand for drugs required for treatment, and a surge in adoption of various types of ulcerative colitis drugs. Moreover, many people prefer to take medications through oral mode rather than injections, hence boosting the growth of the segment during the forecasting period.
|Market size value in 2021||USD 6.2 Billion|
|Market size forecast in 2028||USD 9 Billion|
|Historical Period||2018 to 2020|
|Forecast Period||2022 to 2028|
|Revenue Growth Rate||CAGR of 5.7% from 2022 to 2028|
|Number of Pages||188|
|Number of Tables||330|
|Report coverage||Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling|
|Segments covered||Molecule Type, Disease Type, Route of Administration, Region|
|Country scope||US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria|
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, North America emerged as the leading region in the overall Ulcerative Colitis Market by collecting the maximum revenue share. The high growth of the segment is because of the rise in the number of ulcerative colitis patients, the presence of important companies, the expansion of the healthcare sector, and the presence of new medications in the region. Because of the presence of important companies and the rising prevalence of Ulcerative Colitis in the region, as well as continued financing for the development of new therapies for the treatment of the ailment, North America is likely to lead the ulcerative colitis market.
Free Valuable Insights: Global Ulcerative Colitis Market size to reach USD 9 Billion by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
Strategies deployed in Ulcerative Colitis Market
- Mar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer’s Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.
- Mar-2021: InDex Pharmaceuticals signed an agreement with Parexel Biotech, a trusted global clinical research organization. Through this agreement, the companies would assess the effectiveness and security of the drug consumer cobitolimod for the therapy of average to critical left-sided ulcerative colitis.
- Feb-2021: Merck signed an agreement to acquire Pandion, a clinical-stage biotechnology enterprise designing novel therapeutics. Through this acquisition, Merck, via a subsidiary, would commence a tender provide to acquire all remaining shares of Pandion. Additionally, this acquisition aimed to definite conditions, such as the tender shares representing at least a greatest number of Pandion’s shares of completely-diluted common stock, the termination of the waiting period under the Hart-Scott-Rodino Antitrust enhancement Act, and other conventional situations.
- Mar-2018: Pfizer received a Food and Drug Administration approval for XELJANZ, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients in the U.S with average to serious active ulcerative colitis. Through this approval, XELJANZ would offer adults living with average to serious active ulcerative colitis now have an oral choice that assists accomplish and preserve steroid-free remission.
Scope of the Study
Market Segments Covered in the Report:
- Small Molecules
By Disease Type
By Route of Administration
- North America
- Rest of North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Ajinomoto Co., Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi S.A.
- InDex Pharmaceuticals Holding AB
- Eli Lilly And Company
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
What would be the size of the ulcerative colitis market by 2028?
The ulcerative colitis market size is projected to reach USD 9 billion by 2028.
What are the key driving factors and challenges in the ulcerative colitis market?
Rising incidences of Ulcerative proctitis are increasing are driving the market in coming years, however, concerns about patent expiry and concerns about negative side effects growth of the market.
Who are the leading players in the ulcerative colitis market?
Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
Which segment shows a high revenue share of the ulcerative colitis market in 2021?
The Mild segment acquired maximum revenue share in the Global Ulcerative Colitis Market by Disease Type in 2021; thereby, achieving a market value of $4.5 billion by 2028.
Which region is fastest growing region in the market?
The North America is the fastest growing region in the Global Ulcerative Colitis Market by Region in 2021, and would continue to be a dominant market till 2028.